Project Grant R21TR006265
- Federal Project Grant Award Summary The University of California, Irvine received a $419,398 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on June 16, 2025, with a completion date of June 15, 2027. This award supports research focused on "Accelerating the Translation of Oligonucleotide Therapeutics by Enhancing Delivery." The project addresses a critical bottleneck in oligonucleotide therapeutic (ONT) development—the...
- Federal Grant Award Summary The University of California, Irvine received a $1.32 million Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 15, 2025 through August 31, 2029. This project delivers advanced research and development services to overcome fundamental speed limitations in label-free, single-molecule biosensing applications. The core deliverable is a...
- Federal Project Grant Award Summary The University of California, Irvine received a $493,884 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) awarded June 1, 2026, through May 31, 2031. Under the direction of Dr. Abraham Lee, this award funds the development and advancement of the Arrayed-Droplet Optical Projection Tomography (ADOPT) platform, a microfluidic technology designed to rapidly acquire and...
- Federal Grant Award Summary The University of California, Irvine received a $384,527 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2030. This award funds research to decipher the interactome and biological functions of disordered microproteins—a recently identified class of proteins composed of fewer than 100-150 amino acids encoded by small open...
- Federal Project Grant Award Summary The University of California, Irvine received a $343,554 Project Grant award dated May 1, 2026, from the National Science Foundation's Division of Chemical, Bioengineering, Environmental, and Transport Systems under the Engineering program (CFDA 47.041). This three-year research initiative, extending through April 30, 2029, will deliver a directed evolution workflow for surface-displayed enzymes on Bacillus subtilis spore particles, designed to identify and...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded the University of California, Los Angeles a $420,981 Project Grant effective March 1, 2026, through February 28, 2031, under the Biomedical Research and Research Training program (CFDA 93.859). This award supports directed evolution of biocatalysts for asymmetric hydrogen atom transfer reactions, an interdisciplinary research initiative integrating organic chemistry, protein engineering, bioinorganic...
- Federal Grant Award Summary The University of California, Irvine received a $168,352 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) (CFDA 93.350), effective July 1, 2025 through June 30, 2030, to establish and operate the Institute for Clinical and Translational Science NRSA Postdoctoral Research Training Core (T32 program). The program delivers mentored career development and training services to postdoctoral fellows pursuing clinical and translational...
- Federal Grant Award Summary The University of California, San Diego received a $159,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The award funds the development and validation of a novel transgenic mouse model that combines a B6.TCRA-AMCY reporter mouse with an established NUR77-GFP reporter model to measure T cell receptor...
- Federal Project Grant Award Summary The University of California, San Diego received a $438,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 8, 2025, through June 30, 2027. The award supports basic immunological research focused on understanding the mechanisms that regulate immunoglobulin gene rearrangement, specifically investigating how enhancers and epigenetic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $815,762 to the Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 19, 2026. This Project Grant funds research aimed at developing a quantitative understanding of biophysical constraints on antibody affinity maturation to SARS-CoV-2 spike variants. The research will utilize high-throughput mammalian...
The University of California, Irvine received a $413,771 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded June 1, 2026, with a completion date of May 31, 2028. The project, "Accelerated Antibody Evolution Under Functional Selection," develops an innovative in vitro method for rapid antibody evolution optimized for functional activity rather than antigen binding strength alone. The research focuses on creating allosteric modulators for G protein-coupled receptors (GPCRs)—the largest family of human membrane proteins involved in numerous physiological processes—using an engineered yeast-based system with orthogonal plasmid replication that maintains high mutation rates for antibody evolution while preserving organism viability. The project delivers cutting-edge therapeutic development technology through a microfluidic platform that encapsulates mutating yeast cells producing antibody fragments alongside mammalian GPCR reporter cells, enabling direct quantification of antibody functional activity through fluorescence-based selection. This approach addresses a critical bottleneck in therapeutic antibody development by harnessing evolutionary principles to optimize functional characteristics beyond simple binding affinity, accelerating the translation of antibody-based therapeutics from discovery to clinical application. The award aligns with NCATS's mission to reduce costly delays in the translational research pipeline and deliver new therapeutics to patients more efficiently.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $413.8k | 5/4/26 |